Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL Quick Quote HOWL - Free Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward ...

Werewolf Therapeutics (NASDAQ:HOWL) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company ...

) has been revised to $7.14 / share. This is an increase of 12.00% from the prior estimate of $6.38 dated April 12, 2026. The price target is an average of many targets provided by analysts. The ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...